Skip to content ↓

Suresh sworn in as NSF director

Holdren administers oath of office.
John Holdren ’65, SM ’66, right, formally swears in Subra Suresh as NSF director as Suresh’s wife, Mary, looks on.
Caption:
John Holdren ’65, SM ’66, right, formally swears in Subra Suresh as NSF director as Suresh’s wife, Mary, looks on.
Credits:
Photo: Christy Bowe (ImageCatcher News)

Subra Suresh, former dean of MIT’s School of Engineering, was officially sworn in on Monday as director of the National Science Foundation.

John Holdren ’65, SM ’66, President Barack Obama’s science adviser and director of the Office of Science and Technology Policy, administered the oath of office to Suresh in the Secretary of War Ceremonial Room of the Eisenhower Executive Office Building in Washington.

As NSF director, Suresh will lead a $7.4 billion independent federal agency that supports all fields of science and engineering research, as well as a wide span of educational programs that reach more than 2,000 institutions across the U.S. and involve approximately 200,000 educators, researchers and students. NSF funding accounts for more than half of all non-medical science and engineering basic research at American academic institutions.

Obama nominated Suresh to lead the NSF earlier this year, and the U.S. Senate confirmed the nomination in September. Cynthia Barnhart, Ford Professor of Engineering, has assumed the role of interim dean of the School of Engineering.

Related Links

Related Topics

More MIT News

Rich Nielsen, Volha Charnysh, Kevin Dorst, and Emily Richmond Pollock seated at a table, talking

Building a scholarly community

The SHASS Faculty Fellows Program, administered by the MIT Human Insight Collaborative, is fostering new research projects and creating space for supportive and interdisciplinary discussion.

Read full story

Globular blue and white orbs "examining" single-stranded RNA products and marking them with green checks or red x's

Why are some bacterial genes high in purines?

In certain species of bacteria, the answer lies in shielding RNA transcripts from a quality-control factor called Rho. Understanding the requirements for expressible sequences is critical for expression engineering of therapeutic agents.

Read full story